UNSPSC 51361903: Amobarbital or amylobarbitone

This classification denotes a barbiturate with the molecular formula C11H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GWH6IJ239E, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)- but generally known as amobarbital, which bears US NIH Compound Identifier 2164. amobarbital most often arises in base, natrium, and sodium forms. European Medicines Agency schedules Amobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05468MIG.

UNSPSC 51361903 Amobarbital or amylobarbitone is a Commodity code that nominally describes a specific barbiturate pharmaceutical, yet the recent state and local opportunities tagged under it reflect a broader pharmaceutical and drug-management procurement activity. State and local governments are buying naloxone, opioid-overdose reversal agents, drug deactivation systems, and generic multi-source pharmaceuticals through this code, with issuing bodies spanning county health departments, state human services commissions, and regional cooperative purchasing alliances. The actual procurement scope centers on emergency medical supplies, community health initiatives, prescription fulfillment programs, and generic pharmaceutical distribution networks rather than amobarbital specifically. Issuing bodies include Seminole County, Florida (a county health authority), the Texas Health and Human Services Commission (a state agency), and the Minnesota Multistate Cooperative Purchasing Alliance (a cooperative purchasing vehicle administered by the Minnesota Department of Administration).

Geographic activity is concentrated in Florida, Texas, and Minnesota, with cooperative purchasing extending across multiple states including Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline (note: the due date appears to be a data-entry anomaly); the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program with an April 3, 2026 response deadline; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 due date and July 1, 2026 contract effective date. The mismatch between the code's nominal scope and the actual solicitations suggests either data-entry misclassification or use of this Commodity code as a catchall for pharmaceutical procurement.